Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP-1929 + Pembrolizumab in Recurrent HNSCC
NCT05265013Phase 2Terminated
- Sponsor
- Rakuten Medical, Inc.
- Start
- Apr 2022
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab sarotalocan sodium in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Rakuten Medical, Inc.. Started Apr 2022; status: terminated.
02
Drugs
cetuximab sarotalocan sodium
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05265013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265013.